This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q24.6 | Special Copayment Reduction: V271 (rare disease) |
| B. Synonyms | Congenital heart block |
| C. Adult onset | Likelihood of first onset in adulthood: low — congenital complete atrioventricular block is diagnosed as bradycardia in the fetal to neonatal period. However, mild (first- to second-degree) congenital heart block may be found incidentally in childhood to adulthood. |
| 1. History | First reported by Morquio in 1901; association with maternal antibodies described by Behan in 1966; permanent pacemakers changed the prognosis. |
| 2. Causes | Maternal anti-Ro/SSA and anti-La/SSB antibodies (about 80~90%); associated structural congenital heart defects (about 10~15%); hereditary arrhythmias. |
| 3. Genetics | Ion channel genes such as SCN5A, KCNJ2, and GJA5; maternal HLA-DQ and fetal genetic susceptibility; anti-Ro antibodies are central. |
| 4. General epidemiology | About 1 in 15,000~20,000 live births; about 1~3% in anti-Ro-positive mothers; slightly more common in girls. |
| 5. Pathophysiology | Anti-Ro/SSA antibodies → blockade of L-type Ca²⁺ channels and apoptosis of fetal atrioventricular nodal cells → fibrosis → atrioventricular block. |
| 6. Symptoms | Fetal period: persistent bradycardia (heart rate <55 beats/min); neonates: bradycardia, hydrops; infancy to childhood: exercise intolerance, syncope. |
| 7. Signs | Persistent bradycardia; dissociation between rapid atrial beats (P waves) and slow ventricular beats (QRS); abnormal venous pressure findings (canon A waves). |
| 8. Screening | Weekly fetal echocardiographic surveillance at 18~26 weeks of gestation in anti-Ro/SSA antibody-positive pregnant women is key. |
| 9. Diagnosis | ECG (P-QRS dissociation); fetal echocardiography (mechanical PR interval); Holter; evaluation for associated structural defects. |
| 10. Treatment | Complete atrioventricular block + symptoms/low heart rate → permanent pacemaker implantation; fetal complete block with hydrops → fluorinated corticosteroids and early delivery. |
| 11. Prognosis | Good long-term survival after pacemaker; pacemaker durability and lead problems are the main follow-up issues; poor with associated structural defects. |
| 12. Prevention | Prophylactic HCQ in anti-Ro-positive pregnant women; intensive fetal echocardiographic surveillance at 18~26 weeks of gestation; specialist care for pregnant women at risk of recurrence. |
| 13. References | 10 major clinical guidelines and original papers |
The history of Congenital Heart Block (CHB) begins in 1901, when the Uruguayan physician Morquio described a family with congenital, persistent complete atrioventricular block. The cause was unclear at the time, but later research identified two main etiologies: structural causes (associated congenital heart defects) and autoimmune causes (mediated by maternal antibodies).
In 1966, Behan and Holborow published research showing that in maternal lupus, anti-Ro/SSA antibodies can be transferred to the fetal heart and cause heart block, and subsequently in 1977 Scott et al. established that about 80~90% of congenital complete atrioventricular block is associated with maternal anti-Ro/SSA or anti-La/SSB antibodies. Since the 1980s, advances in fetal echocardiography have made it possible to diagnose fetal bradycardia (atrioventricular block) in utero, and since the 1990s, as permanent pacemaker implantation techniques became standardized in children as well, the prognosis of patients with CHB has improved greatly.
Recently, prophylactic hydroxychloroquine and regular fetal echocardiographic surveillance to prevent fetal heart block in anti-Ro/SSA antibody-positive pregnant women have been included in clinical guidelines.
The causes of congenital heart block are broadly classified into three categories.
Maternal autoantibody-mediated (about 80~90%): Anti-Ro/SSA (anti-Ro52/Ro60) and anti-La/SSB IgG antibodies in the serum of mothers with systemic lupus erythematosus (SLE), Sjögren syndrome, or other connective tissue diseases cross the placenta into the fetal circulation and bind to the fetal cardiac conduction system. These antibodies bind to Ro/La antigens in the atrioventricular node (AV node) and His-Purkinje conduction system, causing fibrosis and inflammation and blocking atrioventricular conduction. The risk of congenital complete atrioventricular block in anti-Ro/SSA antibody-positive pregnant women is about 1~3%, and if a child with CHB has previously been born, the risk of recurrence increases to 12~20%.
Associated structural congenital heart defects (about 10~15%): In congenitally corrected TGA (ccTGA), atrioventricular septal defect (AVSD), single ventricle anomalies, and others, abnormal anatomical position of the atrioventricular node causes CHB. In these cases, it is unrelated to maternal antibodies.
Hereditary causes (rare): Variants in ion channel genes such as SCN5A (sodium channel gene), KCNJ2, and GJA5 (Connexin 40) have been reported and are associated with familial CHB.
The genetic basis of congenital heart block differs according to the cause.
Genetic susceptibility in maternal antibody-mediated CHB: In anti-Ro/SSA antibody-positive pregnant women, CHB does not develop in every fetus but only in some (about 1~3%). This suggests genetic susceptibility on the fetal side. Specific fetal HLA types such as HLA-DRB1*03:01 and HLA-DQ2 have been studied as increasing the risk of CHB. In addition, the fetus's ability to handle antibodies and the level of Ro/La antigen expression in the heart have an influence.
Hereditary CHB: SCN5A (3p21.2-p24) variants can cause atrioventricular block together with Brugada syndrome, long QT syndrome, and others. GJA5 (Connexin 40, 1p35.1) variants are associated with abnormal atrioventricular nodal conduction. KCNJ2 is the cause of Andersen-Tawil syndrome, in which atrioventricular block may be present.
Clinically, in familial CHB or when other cardiac abnormalities are present, ion channel gene panel testing is considered.
Congenital heart block is a rare congenital arrhythmia occurring in about 1 in 15,000~20,000 live births. Maternal autoantibody-mediated CHB accounts for about 80~90% of the total, and anti-Ro/SSA antibody-positive pregnant women have a risk of about 1~3%. Among women with SLE or Sjögren syndrome, the anti-Ro/SSA antibody positivity rate is about 30~40%.
It is reported to be slightly more common in girls than boys (female predominance, about 60~65%). This reflects that maternal lupus and Sjögren syndrome themselves are overwhelmingly more common in women. Worldwide, the frequency of anti-Ro/SSA antibody-positive pregnant women is about 0.1~0.5%.
In Korea, prenatal CHB screening and neonatal CHB management are carried out within a collaborative system of rheumatology and pediatric cardiology, and specialist follow-up is supported through Special Copayment Reduction registration (V271).
The pathophysiology of CHB mediated by maternal anti-Ro/SSA antibodies proceeds as follows.
① Maternal IgG (anti-Ro52, anti-Ro60, anti-La/SSB) that has crossed the placenta binds to atrioventricular nodal cells and His bundle cells of the fetal heart. ② Anti-Ro52 antibodies cross-react with L-type calcium channels on the cell surface, inhibiting channel function and slowing atrioventricular conduction velocity. ③ The antibodies enter the cells and promote apoptosis, and intracellular Ro/La antigens released from dead cells trigger further inflammatory responses. ④ In the process of clearing cell debris, macrophages secrete cytokines that promote fibrosis (TGF-β, IL-6, etc.). ⑤ Fibrosis accumulates around the atrioventricular node and His bundle, completing irreversible atrioventricular conduction block.
This process is most active mainly at 18~24 weeks of gestation (the peak period of atrioventricular node development), so fetal echocardiographic surveillance during this period is particularly important. It can progress from first-degree (PR prolongation) → second-degree (partial block) → third-degree (complete block), and the transition from second- to third-degree can occur rapidly.
Fetal period: A persistent decrease in fetal heart rate (usually 55~80 beats/min or below) is found during fetal echocardiographic surveillance. Fetuses with complete atrioventricular block maintain a compensatory heart rate of 40~55 beats/min; if it is lower than this or accompanied by reduced ventricular function, hydrops fetalis can develop. Hydrops fetalis presents as generalized edema and pleural effusion/ascites and is associated with a high risk of death.
Neonatal period: After birth, bradycardia (heart rate <55 beats/min), cyanosis, feeding difficulty, and lethargy appear. Even with a resting heart rate of 40~50 beats/min, maintaining cardiac output is difficult in the neonatal period, and heart failure can develop.
Infancy to childhood: Mild cases may grow up asymptomatic, but because an appropriate increase in heart rate during exercise is not possible, exercise intolerance appears. Presyncopal symptoms (dizziness, pallor) or syncope can occur. Dilated cardiomyopathy may also progress because of the inability of the heart rate to adapt.
Complications in adulthood: In those who survive to adulthood without a pacemaker, the risks of bradycardia-related heart failure, arrhythmias (ventricular tachycardia), and syncope persist.
Auscultation findings: The characteristic heart sound pattern in complete atrioventricular block is a regular but slow heartbeat (heart rate 40~60 beats/min). The intensity of S1 varies with the atrioventricular relationship, and at times a cannon sound (cannon S1) is heard—it occurs when the atria and ventricles contract simultaneously.
Jugular venous findings: When the tricuspid valve is closed at the moment the atrium contracts, cannon A waves are observed in the jugular vein. This is important physical evidence of complete atrioventricular block.
ECG findings: ① Complete (third-degree) atrioventricular block: P waves (atrial beats) and QRS complexes (ventricular beats) occur independently of each other (AV dissociation), and the atrial rate (P waves) is much faster than the ventricular rate (QRS). A wide QRS (>120ms) suggests an ectopic ventricular rhythm, and a narrow QRS suggests a junctional escape rhythm below the atrioventricular node. ② First-degree block: PR interval prolongation (>200ms). ③ Second-degree block (Mobitz type I or II): some P waves are not conducted.
Echocardiographic findings: Reduced left ventricular function (a dilated cardiomyopathy pattern), ventricular enlargement, and diastolic dysfunction may be present.
Fetal surveillance in anti-Ro/SSA antibody-positive pregnant women: Maternal anti-Ro/SSA and anti-La/SSB antibodies are measured before pregnancy or in early pregnancy. In antibody-positive pregnant women, fetal echocardiography (including measurement of the mechanical PR interval) is performed every 1~2 weeks during 16~26 weeks of gestation (the vulnerable period for CHB development) to detect fetal atrioventricular conduction abnormalities early. A mechanical PR interval >150ms suggests first-degree block.
Prophylactic hydroxychloroquine (HCQ): Studies (such as the PATCH study) are accumulating showing that taking HCQ (hydroxychloroquine) 400mg/day in anti-Ro/SSA antibody-positive pregnant women reduces the risk of congenital heart block by about 50~70%, and it is currently recommended in several guidelines.
Neonatal ECG screening: In neonates at high risk of CHB (born to anti-Ro/SSA-positive mothers), an ECG immediately after birth is recommended.
Electrocardiogram (ECG): The basic diagnostic tool for congenital heart block. In complete (third-degree) atrioventricular block, complete dissociation of P waves and QRS is confirmed. First- and second-degree blocks are also diagnosed by ECG.
Fetal echocardiography: The standard for fetal diagnosis. Simultaneous M-mode or tissue Doppler techniques are used to measure the mechanical PR interval between fetal atrial contraction (A wave of mitral or pulmonary venous flow) and ventricular contraction (onset of aortic or pulmonary arterial flow). A mechanical PR interval >150ms is judged abnormal.
24-hour Holter ECG: Evaluates the minimum heart rate, diurnal heart rate variation, arrhythmias correlated with syncope, and the presence of ventricular tachycardia. Provides important information for determining pacemaker indications.
Echocardiography: Evaluation of left ventricular function and size and associated structural defects (ccTGA, AVSD, etc.).
Maternal antibody testing: Confirmation of etiology by measuring anti-Ro/SSA (anti-Ro52, anti-Ro60) and anti-La/SSB antibodies.
Electrophysiologic study (EPS): Used before pacemaker insertion to evaluate the exact site of block in the conduction system and the stability of escape rhythms.
Pacemaker indications: Cases of complete atrioventricular block requiring pacemaker implantation: ① resting heart rate <55 beats/min ② symptoms (syncope, exercise intolerance, heart failure) ③ reduced left ventricular function ④ associated structural heart defects ⑤ development of dilated cardiomyopathy. Even in asymptomatic complete atrioventricular block, there is a trend toward recommending pacemaker insertion if the heart rate is persistently <55 beats/min.
Pacemaker implantation: In children, the pacemaker is inserted by an epicardial or transvenous approach depending on body weight and chest size. In neonates and infants, the epicardial approach is mainly used, and in adults the transvenous approach is standard. Dual-chamber pacemakers (atrioventricular synchrony) are hemodynamically more advantageous than single ventricular pacemakers.
Fetal complete atrioventricular block and hydrops: When fetal hydrops is present, dexamethasone (dexamethasone 4mg/day) or betamethasone may be given to the mother in an attempt to suppress inflammation, but evidence of efficacy is limited. If fetal hydrops worsens, early delivery (preterm delivery with preparation for immediate pacemaker insertion) is considered.
Treatment of maternal autoimmunity: Prophylactic HCQ (antibody-positive pregnant women). Immunosuppressive treatment such as steroids when SLE is active.
The prognosis of congenital heart block varies greatly depending on the type of cause, the presence of associated defects, and whether pacemaker treatment is given.
Isolated maternal antibody-mediated CHB: When it occurs in isolation without structural defects, the long-term prognosis after pacemaker implantation is relatively good. Those who maintain a heart rate of 55 beats/min or more without a pacemaker can live asymptomatically for decades. However, the prognosis becomes poor if dilated cardiomyopathy develops or ventricular tachycardia is induced.
After pacemaker implantation: 10~20-year survival is 85~95%, but repeated surgery is needed for lead fracture, electrode growth problems, and battery depletion. Those who survive to adulthood undergo an average of 2~3 or more pacemaker-related operations.
Associated structural defects: When complex heart defects such as ccTGA and AVSD are present, the prognosis is worse than in isolated CHB, and surgical correction of the defect and pacemaker implantation must be planned together.
Prophylactic hydroxychloroquine (HCQ): In anti-Ro/SSA antibody-positive pregnant women, taking HCQ 400mg/day significantly reduces the risk of congenital heart block (risk reduction 50~70%). It is currently recommended in the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines for pregnant women.
Intensive fetal echocardiographic surveillance: In anti-Ro/SSA antibody-positive pregnant women, fetal echocardiography is performed every 1~2 weeks during 16~26 weeks of gestation to detect first-degree block early and monitor progression. Some guidelines include attempts to suppress progression to third-degree block by giving maternal steroids (fluorinated corticosteroids) immediately upon first-degree block.
Pregnant women at risk of recurrence: If a child with CHB was previously born, the risk of recurrence is high at 12~20%, so more intensive prenatal surveillance and management at a specialized center are needed.
Prevention after pacemaker: Prevention of infective endocarditis (pacemaker leads are a high-risk structure), regular pacemaker follow-up checks (checking battery and lead status).
Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis. Arthritis Rheum. 2001;44(8):1832-1835. PMID: 11508440.
Buyon JP, Clancy RM, Friedman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal/fetal dyad at risk. J Intern Med. 2009;265(6):653-662. DOI: 10.1111/j.1365-2796.2009.02100.x. PMID: 19438853.
Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011;124(18):1927-1935. DOI: 10.1161/CIRCULATIONAHA.111.033894. PMID: 21969015.
Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis. 2003;62(10):1010-1012. PMID: 12972484.
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. PMID: 32860028.
Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol. 2001;37(1):238-242. PMID: 11153746.
Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. J Am Coll Cardiol. 2002;39(1):130-137. PMID: 11755299.
Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008;117(4):485-493. DOI: 10.1161/CIRCULATIONAHA.107.707661. PMID: 18172032.
Izmirly P, Kim M, Friedman DM, et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J Am Coll Cardiol. 2020;76(3):292-302. DOI: 10.1016/j.jacc.2020.05.045. PMID: 32674790.
Bergman G, Wahren-Herlenius M, Sonesson SE. Diagnostic precision of Doppler flow echocardiography in fetuses at risk for congenital heart block. Ultrasound Obstet Gynecol. 2010;35(4):451-455. DOI: 10.1002/uog.7487. PMID: 20069557.